no it hasn’t extended survival by 6 months. That’s a simplistic but wrong interpretation of the data.
—Gotta love it ..1. do small uncontrolled non randomised trial, 2. get a result, 3. stick result up against other trials and despite the large level of error (confidence interval in LuPIN for OS is 10-28 months so according to stats a plausible result is Nox adds nothing to LuPSMA) 4. claim the product is now proven and ready to become standard of care! We’ve seen enough of that with Covid trials. Then again the market liked it so well done to you holders!
but hey if I’m a Novartis exec sitting in Basel getting all excited about this little trial whom do I go to to do my due diligence to verify the data- who owns it- NOX or St Vincent’s?
any update on Covid trial?
LuPIN abstract, page-12
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
